Research programme: oncogenic adaptor/scaffolding proteins targetting therapeutics - Ambagon Therapeutics
Alternative Names: Program 1Latest Information Update: 28 Jan 2022
At a glance
- Originator Ambagon Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 06 Jan 2022 Early research in Cancer in USA (unspecified route) before January 2022 (Ambagon Therapeutics pipeline, January 2022)
- 06 Jan 2022 Ambagon Therapeutics intends to nominate first clinical candidate by second half of 2023 (Ambagon Therapeutics pipeline, January 2022)